Cullinan Therapeutics, Inc.
- CGEM
- NASDAQ
- Biotechnology
- Immuno-Oncology
- Cancer Therapeutics
$13.54
Today +4.76%Quote Oct 19, 2026, 03:24 PM UTC
−39.47%over the last month
Max drawdown −40.3%From 1-month high −40.3%3 months −26.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$832.4M
Quote Oct 19
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$34.75
+156.6% from here
Floor
$13.53
0.1% below price
Where the price sits
8 analysts
Analyst range, low to high
$27.00$40.00
- Price $13.54
- Resistance $14.33
- Consensus $34.75
The price is just above its floor. Analysts' average target sits about 157% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CGEMPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
109
Founded
2016